Recent Analysts’ Ratings Changes for Catalyst Pharmaceuticals (CPRX)

A number of research firms have changed their ratings and price targets for Catalyst Pharmaceuticals (NASDAQ: CPRX):

• 11/16/2025 – Catalyst Pharmaceuticals was upgraded by analysts at Wall Street Zen from a “hold” rating to a “buy” rating.
• 11/8/2025 – Catalyst Pharmaceuticals was downgraded by analysts at Wall Street Zen from a “buy” rating to a “hold” rating.
• 11/7/2025 – Catalyst Pharmaceuticals had its “outperform” rating reaffirmed by analysts at Oppenheimer Holdings, Inc.. They now have a $33.00 price target on the stock.
• 11/7/2025 – Catalyst Pharmaceuticals had its price target raised by analysts at Citigroup Inc. from $31.00 to $33.00. They now have a “buy” rating on the stock.
• 10/12/2025 – Catalyst Pharmaceuticals was upgraded by analysts at Wall Street Zen from a “hold” rating to a “buy” rating.
• 10/8/2025 – Catalyst Pharmaceuticals had its “hold (c+)” rating reaffirmed by analysts at Weiss Ratings.
• 10/4/2025 – Catalyst Pharmaceuticals was downgraded by analysts at Wall Street Zen from a “buy” rating to a “hold” rating.
• 9/27/2025 – Catalyst Pharmaceuticals had its “hold (c+)” rating reaffirmed by analysts at Weiss Ratings.

Insiders Place Their Bets

In other Catalyst Pharmaceuticals news, insider Brian Elsbernd sold 30,000 shares of the company’s stock in a transaction that occurred on Monday, September 8th. The shares were sold at an average price of $20.30, for a total value of $609,000.00. Following the completion of the transaction, the insider directly owned 271,039 shares in the company, valued at $5,502,091.70. This represents a 9.97% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders have sold a total of 80,000 shares of company stock worth $1,596,200 over the last quarter. 10.40% of the stock is owned by insiders.

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.